MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Halozyme Therapeutics Company Profile (NASDAQ:HALO)

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (?)
Ratings Breakdown: 1 Sell Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $15.63 (85.13% upside)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Piper JaffrayReiterated RatingOverweight$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Canaccord GenuityReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Jefferies GroupReiterated RatingSell$6.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016BarclaysLower Price TargetOverweight$27.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2015Citigroup Inc.Initiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015JPMorgan Chase & Co.Boost Price TargetOverweight$20.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015MLV & Co.Reiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2015BMO Capital MarketsSet Price TargetBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Halozyme Therapeutics (NASDAQ:HALO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.14)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2012($0.11)$0.14ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2011($0.03)$0.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.20)($0.17)($0.19)
Q2 20161($0.28)($0.28)($0.28)
Q3 20161($0.28)($0.28)($0.28)
Q4 20161($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)
Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Halozyme Therapeutics (NASDAQ:HALO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
DateHeadline
06/25/16 04:06 PMHalozyme Therapeutics Inc. (HALO) Jumps 6.49% on June 23 - Equities.com
06/23/16 07:15 AMWhich way Halozyme Therapeutics (NASDAQ:HALO) earnings moved?
06/22/16 09:00 AMHalozyme Therapeutics (NASDAQ:HALO) Analyst Rating Consensus - TheFounders Daily
06/20/16 04:09 PMThis Weeks Broker Views For Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Fiscal Standard
06/18/16 03:56 PMRecent Update on Price Movements: Halozyme Therapeutics, Inc. (NASDAQ:HALO) , Quintiles Transitional Holdings ... - Street Updates
06/16/16 08:40 AMTake a look at Price Moves: Galena Biopharma, Inc. (NASDAQ:GALE) , Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Street Updates
06/15/16 04:24 PMPrice Fluctuations to Observe: Halozyme Therapeutics, Inc. (NASDAQ:HALO) , Endologix, Inc. (NASDAQ:ELGX) - Street Updates
06/13/16 07:04 AMHC Stocks in Hub: Catalent Inc (NYSE:CTLT), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - share market updates (press release)
06/10/16 06:28 PMETF’s with exposure to Halozyme Therapeutics, Inc. : June 10, 2016 -
06/09/16 04:31 PMStocks Attracts Frontline Trades- Restoration Hardware (NYSE:RH), Halozyme Therapeutics (NASDAQ:HALO), Mitel ... - Seneca Globe
06/09/16 04:31 PMAnalyst Ratings on: Halozyme Therapeutics, Inc. (NASDAQ:HALO), WPCS International Incorporated (NASDAQ:WPCS) - Beacon Chronicle
06/08/16 04:38 PMWhat should one expect from? - Halozyme Therapeutics, Inc. (NASDAQ:HALO), Titan Pharmaceuticals Inc. (NASDAQ ... - Beacon Chronicle
06/08/16 04:38 PMWhat should one expect from? - Halozyme Therapeutics, Inc. (NASDAQ:HALO), Titan Pharmaceuticals Inc. (NASDAQ ... - Beacon Chronicle
06/08/16 08:18 AMHalozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance - [at noodls] - SAN DIEGO, June 8, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has entered into ...
06/08/16 08:03 AMHALOZYME THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D -
06/08/16 07:01 AMAnalyst Overview: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - News Oracle
06/08/16 07:01 AMHalozyme Therapeutics Inc. (HALO) is Trading Lower on Unusual Volume for June 06 - Equities.com
06/07/16 04:30 PMToday's Weak On High Volume Stock: Halozyme Therapeutics (HALO) - TheStreet.com
06/07/16 04:52 AMPerformance report of the company: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - News Oracle
06/06/16 04:14 PMHC Stocks To Observe: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Amgen, Inc. (NASDAQ:AMGN) - share market updates (press release)
06/06/16 04:14 PMStocks Earnings Overview: CYS Investments, Inc. (NYSE:CYS), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Beacon Chronicle
06/06/16 07:53 AMCelldex Therapeutics, Inc. (NASDAQ:CLDX) & Halozyme Therapeutics, (NASDAQ:HALO) healthcare Stocks to Watch - Wall Street 24
06/06/16 07:53 AMPortfolio Of Healthcare Movers: Gilead Sciences, Inc. (NASDAQ:GILD) , Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Is stories
06/06/16 07:26 AMHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : June 6, 2016 -
06/05/16 07:17 PM8:17 pm Halozyme Therapeutics presents stage one efficacy and safety analysis of Phase 2 study in patients treated with PEGPH20; supports ongoing Phase 3 HALO 301 clinical study -
06/05/16 04:17 PMPerformance Review for Halozyme Therapeutics, Inc. (NASDAQ:HALO) - HNN
06/05/16 04:17 PMPerformance Review for Halozyme Therapeutics, Inc. (NASDAQ:HALO) - HNN
06/05/16 07:02 AMHalozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer ... - PR Newswire (press release)
06/04/16 08:08 AMHalozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 - [at noodls] - SAN DIEGO, June 4, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced results from a final analysis ...
06/03/16 04:40 PMAnalytical Report of the Stocks: HCP, Inc. (NYSE:HCP), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Beacon Chronicle
06/03/16 04:40 PMTwo Healthcare Most Traded Stocks: Gilead Sciences, Inc. (NASDAQ:GILD) , Halozyme Therapeutics, Inc. (NASDAQ ... - Is stories
06/02/16 04:35 PMBroker Watchlist: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Share Trading News - Broker Watchlist: Halozyme Therapeutics, Inc. (NASDAQ:HALO)Share Trading News02/24/2016 – Halozyme Therapeutics, Inc. had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 16 price target on the stock. 02/01/2016 – Canaccord Genuity began new coverage on Halozyme Therapeutics, Inc. giving the ...and more »
06/02/16 04:35 PMStock's Earnings Analysis Report: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Level 3 Communications, Inc. (NYSE ... - Beacon Chronicle - Beacon ChronicleStock's Earnings Analysis Report: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Level 3 Communications, Inc. (NYSE ...Beacon ChronicleLast Trade: The Company closed its last session at $9.96 with the loss of -0.99%. The market capitalization of the company is $1.27 Billion, with the average Volume of 1.75 Million. The stock currently has its 52-Week High range of $25.25 and 52-week ...and more »
06/02/16 07:04 AMTarget Price and Stock Performance Rundown for Halozyme Therapeutics, Inc. (NASDAQ:HALO) - HNN - Target Price and Stock Performance Rundown for Halozyme Therapeutics, Inc. (NASDAQ:HALO)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Halozyme Therapeutics, Inc.and more »
06/02/16 07:04 AMTwo Healthcare Stock quotes to Observe: Novavax, Inc. (NASDAQ:NVAX) , Halozyme Therapeutics, Inc. (NASDAQ ... - Is stories - Is storiesTwo Healthcare Stock quotes to Observe: Novavax, Inc. (NASDAQ:NVAX) , Halozyme Therapeutics, Inc. (NASDAQ ...Is storiesNovavax, Inc. (NASDAQ:NVAX) increased +0.82% to $6.14 while traded 7.48 million shares on 6/1/2016. The stock price negotiated for value between $6.01 to $6.21 in recent trading session. During the past 52 weeks, the stock's price witnessed a minimum ...and more »
06/01/16 04:39 PMStock Earnings Overview: GrubHub Inc. (NYSE:GRUB), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Beacon Chronicle - Beacon ChronicleStock Earnings Overview: GrubHub Inc. (NYSE:GRUB), Halozyme Therapeutics, Inc. (NASDAQ:HALO)Beacon ChronicleLast Trade: The Company closed its last session at $25.59 with the gain of 2.48%. The market capitalization of the company is $2.13 Billion, with the average Volume of 1.76 Million. The stock currently has its 52-Week High range of $40.99 and 52-week ...and more »
06/01/16 07:02 AMNoteworthy Analyst's Rating to Observe: IDEXX Laboratories, Inc. (NASDAQ:IDXX) , Halozyme Therapeutics, Inc ... - Street Updates - Noteworthy Analyst's Rating to Observe: IDEXX Laboratories, Inc. (NASDAQ:IDXX) , Halozyme Therapeutics, Inc ...Street UpdatesIn the past trading session, Halozyme Therapeutics, Inc. (NASDAQ:HALO) highlighted upward shift of +0.60% or +0.06 points to $10.06. The company traded a volume of 2.01 million shares over average volume of 1.77 million shares. Trailing twelve month ...and more »
05/31/16 04:33 PMHC Stocks Summary: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - share market updates (press release) - share market updates (press release)HC Stocks Summary: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Halozyme Therapeutics, Inc. (NASDAQ:HALO)share market updates (press release)Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ended Friday session in red amid volatile trading. The shares closed down -0.01 points or -0.13% at $7.43 with 641,594.00 shares getting traded. Post opening the session at $7.44, the shares hit an ...
05/31/16 04:33 PMNews Sentiment For Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Investor Newswire - News Sentiment For Halozyme Therapeutics, Inc. (NASDAQ:HALO)Investor NewswireHalozyme Therapeutics, Inc. has a 90 in the recent session. By this score, sell-side analysts examining the equity, have given a 13-month price estimate of $12.583 on the stock. It is arrived at by taking into account the stock recommendations of 3 ...and more »
05/26/16 07:16 AMHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : May 26, 2016 -
05/25/16 05:33 PMHealthcare Stock's Latest Update: Pfizer, Inc. (NYSE:PFE) , Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Is stories - Healthcare Stock's Latest Update: Pfizer, Inc. (NYSE:PFE) , Halozyme Therapeutics, Inc. (NASDAQ:HALO)Is storiesPfizer, Inc. (NYSE:PFE) initiated the shares trading at $33.69 and showed positive change of +1.28% while the stock's final trade was registered at $ 34.10. However, its previous closing price was seen at $33.67. The stock negotiated total number of 28 ...and more »
05/25/16 08:53 AMGrowth Estimate Overview: Halozyme Therapeutics, Inc. (NASDAQ:HALO), AMN Healthcare Services, Inc. (NYSE:AHS) - News Oracle - News OracleGrowth Estimate Overview: Halozyme Therapeutics, Inc. (NASDAQ:HALO), AMN Healthcare Services, Inc. (NYSE:AHS)News OracleThe stock gained 4.08% and closed its last session at $9.70. The Company has the market capitalization of 1.28 Billion. The 52-Week Range ranges between $6.96 and $25.25. The stock traded with the Volume of 1.48 Million in the last trading day whereas, ...
05/24/16 05:40 PMHealthcare Stocks within Traders Concentration: Celldex Therapeutics, Inc. (NASDAQ:CLDX) , Halozyme Therapeutics ... - Is stories - Healthcare Stocks within Traders Concentration: Celldex Therapeutics, Inc. (NASDAQ:CLDX) , Halozyme Therapeutics ...Is storiesCelldex Therapeutics, Inc. (NASDAQ:CLDX) increased +5.96% to $4.27 while traded 4.25 million shares on 5/23/2016. The stock price negotiated for value between $4.03 to $4.50 in recent trading session. During the past 52 weeks, the stock's price ...and more »
05/23/16 10:34 AMHC Sector update: Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - share market updates (press release) - share market updates (press release)HC Sector update: Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), Halozyme Therapeutics, Inc. (NASDAQ:HALO)share market updates (press release)Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) ended Friday session in green amid volatile trading. The shares closed up +0.023 points or 4.00% at $0.600 with 408,435.00 shares getting traded. Post opening the session at $0.57, the shares hit an ...
05/22/16 05:04 PMHalozyme Therapeutics, Inc. (NASDAQ:HALO) Broker Price Targets For The Coming Week - Share Trading News - Halozyme Therapeutics, Inc. (NASDAQ:HALO) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO). The latest reports which are currently in issue on Sunday 22nd of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/20/16 09:11 AMAlpha One Assigns Impact Score Of 90 To Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Investor Newswire - Alpha One Assigns Impact Score Of 90 To Halozyme Therapeutics, Inc. (NASDAQ:HALO)Investor NewswireAlpha One analyzed the various web articles published on Halozyme Therapeutics, Inc. (NASDAQ:HALO), and thereafter it gave company a daily sentiment score of 0.31. The entity designs algorithm based assessment to known stock sentiment on stock after ...and more »
05/18/16 12:04 PMHALOZYME THERAPEUTICS INC Financials -
05/18/16 09:45 AMHalozyme Therapeutics, Inc. (NASDAQ:HALO) , Zimmer Biomet Holdings, Inc. (NYSE:ZBH): Trading updates about two ... - Street Updates - Halozyme Therapeutics, Inc. (NASDAQ:HALO) , Zimmer Biomet Holdings, Inc. (NYSE:ZBH): Trading updates about two ...Street UpdatesHalozyme Therapeutics, Inc. (NASDAQ:HALO) diminished -2.75%, closing at $8.83 after floating between $8.79 and $9.29. The company has market capitalization of $1.13B. It has twelve month low of $6.96 and twelve month high of $25.25. The recent traded ...
05/18/16 09:44 AMHalozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference - PR Newswire (press release) - Halozyme Therapeutics To Present At The UBS 2016 Global Health Care ConferencePR Newswire (press release)SAN DIEGO, May 17, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2016 Global Health Care Conference in New York, on Tuesday, May 24 at 2:30 p.m. ET/11:30 a.m. PT. Laurie Stelzer, chief financial ...Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported a loss in its first quarter.Inside Trade2 Sizzling Hot Biotechnology Stocks: Halozyme Therapeutics (HALO), Albany Molecular Research (AMRI)ZergwatchAre Analysts Bearish Halozyme Therapeutics, Inc. (NASDAQ:HALO) After Last Week?Franklin Independentall 6 news articles »
05/17/16 05:28 PMHalozyme Therapeutics, Inc. (NASDAQ:HALO) reported a loss in its first quarter. - Inside Trade - Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported a loss in its first quarter.Inside TradeHalozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs ...Scorching Hot Biotech Stocks Tape: ChemoCentryx, Inc. (CCXI), Halozyme Therapeutics, Inc. (HALO)ZergwatchAre Analysts Bearish Halozyme Therapeutics, Inc. (NASDAQ:HALO) After Last Week?Franklin Independentall 3 news articles »
About Halozyme Therapeutics

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company's development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: HALO
  • CUSIP: 40637H10
Key Metrics:
  • Previous Close: $9.19
  • 50 Day Moving Average: $9.21
  • 200 Day Moving Average: $10.54
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.08B
  • Current Quarter EPS Consensus Estimate: $-1.03 EPS
Additional Links:
Halozyme Therapeutics (NASDAQ:HALO) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha